Drugs / OMFILOCTOCOG ALFA
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02888223 | Sep 2016 → Feb 2017 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07437404 | Apr 2024 → Dec 2028 expected | hemophilia A | Sinocelltech Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02921945 | Oct 2016 → Dec 2017 | hemophilia A | Sinocelltech Ltd. | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05888870 Comparator | Nov 2023 → Dec 2026 expected | hemophilia A | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OMFILOCTOCOG ALFA | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594605 ↗ |
| Known as | rFVIII | “low-dose domestic rFVIII (SCT800) (50IU/kg TIW)” NCT05888870 ↗ |
| Known as | SCT800 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05888870 ↗ |
| Modality | Protein / enzyme biologic | “B-domain Deleted Recombinant Factor VIII” NCT02888223 ↗ |
| Route | Intravenous | “15-50 IU/kg SCT800 is intravenously” NCT07437404 ↗ |
| Target | F8 | “Coagulation factor VIII exogenous protein” CHEMBL4594605 ↗ |